Rac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine Therapy

[1]  A. Malliri,et al.  Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms , 2016, Small GTPases.

[2]  C. Mulder,et al.  Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease , 2016, Therapeutic drug monitoring.

[3]  U. Hofmann,et al.  Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases. , 2016, Journal of Crohn's & colitis.

[4]  M. Overduin,et al.  Structural Mechanisms and Drug Discovery Prospects of Rho GTPases , 2016, Cells.

[5]  Ta-Chiang Liu,et al.  Genetics and Pathogenesis of Inflammatory Bowel Disease. , 2016, Annual review of pathology.

[6]  Jin-young Shin,et al.  Thiopurine Prodrugs Mediate Immunosuppressive Effects by Interfering with Rac1 Protein Function* , 2016, The Journal of Biological Chemistry.

[7]  C. Mulder,et al.  Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease , 2015, Therapeutic drug monitoring.

[8]  D. Turner,et al.  Rac1 Polymorphisms and Thiopurine Efficacy in Children With Inflammatory Bowel Disease , 2015, Journal of pediatric gastroenterology and nutrition.

[9]  Shiyu Xiao,et al.  Role of Rho kinase signal pathway in inflammatory bowel disease. , 2015, International journal of clinical and experimental medicine.

[10]  S. Vikingsson,et al.  Novel assay to improve therapeutic drug monitoring of thiopurines in inflammatory bowel disease. , 2014, Journal of Crohn's & colitis.

[11]  V. de Waard,et al.  6-Mercaptopurine Reduces Macrophage Activation and Gut Epithelium Proliferation Through Inhibition of GTPase Rac1 , 2014, Inflammatory bowel diseases.

[12]  W. Sandborn,et al.  A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  C. Der,et al.  Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease , 2014, Oncogene.

[14]  K. Faber,et al.  Suppression of p21Rac Signaling and Increased Innate Immunity Mediate Remission in Crohn’s Disease , 2014, Science Translational Medicine.

[15]  P. Rutgeerts,et al.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.

[16]  Y. Falck‐Ytter,et al.  AGA American Gastroenterological Association Institute Guideline on the Use of Thiopurines , Methotrexate , and Anti – TNF-a Biologic Drugs for the Induction and Maintenance of Remission in In fl ammatory Crohn ’ s Disease , 2022 .

[17]  K. Rajalingam,et al.  Small Rho GTPases in the control of cell shape and mobility , 2013, Cellular and Molecular Life Sciences.

[18]  R. Eliakim,et al.  Thiopurine Effectiveness in Patients with Crohn's Disease: A Study of Genetic and Clinical Predictive Factors , 2013, Inflammatory bowel diseases.

[19]  M. Glogauer,et al.  Rac2-Deficiency Leads to Exacerbated and Protracted Colitis in Response to Citrobacter rodentium Infection , 2013, PloS one.

[20]  W. Sandborn,et al.  Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.

[21]  A. Paulussen,et al.  Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. , 2012, Journal of Crohn's & colitis.

[22]  Yi Zheng,et al.  Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammation. , 2012, Chemistry & biology.

[23]  M. Kazanietz,et al.  Rac signaling in breast cancer: a tale of GEFs and GAPs. , 2012, Cellular signalling.

[24]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[25]  N. Hunt,et al.  Gp91phox contributes to the development of experimental inflammatory bowel disease , 2011, Immunology and cell biology.

[26]  Judy H. Cho,et al.  NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2 , 2011, Gut.

[27]  F. Casellas,et al.  Thiopurine methyl‐transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine‐treated inflammatory bowel disease patients , 2011, Alimentary pharmacology & therapeutics.

[28]  Judy H. Cho,et al.  Single nucleotide polymorphisms that increase expression of the guanosine triphosphatase RAC1 are associated with ulcerative colitis. , 2011, Gastroenterology.

[29]  J. Lo-Guidice,et al.  Evidence for a functional genetic polymorphism of the Rho-Gtpase Rac1: Implication in azathioprine response? , 2011 .

[30]  J. Lo-Guidice,et al.  Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response? , 2011, Pharmacogenetics and genomics.

[31]  R. Gearry,et al.  Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease , 2011, Inflammatory bowel diseases.

[32]  C. Germer,et al.  Differential role of Rho GTPases in intestinal epithelial barrier regulation in vitro , 2011, Journal of cellular physiology.

[33]  Y. Schneider,et al.  Regulation of small GTPases at epithelial cell-cell junctions , 2011, Molecular membrane biology.

[34]  E. Szigethy,et al.  Inflammatory bowel disease. , 2011, Pediatric clinics of North America.

[35]  A. Ridley,et al.  Rac Activation by the T-Cell Receptor Inhibits T Cell Migration , 2010, PloS one.

[36]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[37]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[38]  V. V. van Hinsbergh,et al.  Driving Rho GTPase activity in endothelial cells regulates barrier integrity , 2009, Thrombosis and Haemostasis.

[39]  D. Hommes,et al.  [Guideline 'Diagnosis and treatment of inflammatory bowel disease in adults'. I. Diagnosis and treatment]. , 2010, Nederlands tijdschrift voor geneeskunde.

[40]  G. Peters,et al.  On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance. , 2009, Current drug metabolism.

[41]  Victor L. J. Tybulewicz,et al.  Rho family GTPases and their regulators in lymphocytes , 2009, Nature Reviews Immunology.

[42]  T. Merriman,et al.  Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population-based cohort , 2008, Genes and Immunity.

[43]  J. Gisbert,et al.  Comparative effectiveness of azathioprine in Crohn’s disease and ulcerative colitis: prospective, long‐term, follow‐up study of 394 patients , 2008, Alimentary pharmacology & therapeutics.

[44]  M. Kazanietz,et al.  Chimaerins: GAPs that bridge diacylglycerol signalling and the small G-protein Rac. , 2007, The Biochemical journal.

[45]  X. Bustelo,et al.  GTP‐binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo , 2007, BioEssays : news and reviews in molecular, cellular and developmental biology.

[46]  J. Tcherkezian,et al.  Current knowledge of the large RhoGAP family of proteins , 2007, Biology of the cell.

[47]  A. Timmer,et al.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2007, The Cochrane database of systematic reviews.

[48]  L. Johnson,et al.  Rac1 mediates intestinal epithelial cell apoptosis via JNK. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[49]  G. Bokoch,et al.  Regulation of the phagocyte NADPH oxidase by Rac GTPase. , 2006, Antioxidants & redox signaling.

[50]  D. M. Rose.  The role of the α4 integrin-paxillin interaction in regulating leukocyte trafficking , 2006, Experimental & Molecular Medicine.

[51]  M. Neurath,et al.  Azathioprine Suppresses Ezrin-Radixin-Moesin-Dependent T Cell-APC Conjugation through Inhibition of Vav Guanosine Exchange Activity on Rac Proteins , 2006, The Journal of Immunology.

[52]  U. Hofmann,et al.  6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[53]  C. Dermardirossian,et al.  GDIs: central regulatory molecules in Rho GTPase activation. , 2005, Trends in cell biology.

[54]  Linda Yang,et al.  Novel intermediate of Rac GTPase activation by guanine nucleotide exchange factor. , 2005, Biochemical and biophysical research communications.

[55]  G. Bokoch.  Regulation of innate immunity by Rho GTPases. , 2005, Trends in cell biology.

[56]  C. Der,et al.  GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors , 2005, Nature Reviews Molecular Cell Biology.

[57]  M. Peppelenbosch,et al.  T cell apoptosis and inflammatory bowel disease , 2004, Gut.

[58]  L. Genestier,et al.  Differential Control of Cell Cycle, Proliferation, and Survival of Primary T Lymphocytes by Purine and Pyrimidine Nucleotides1 , 2003, The Journal of Immunology.

[59]  M. Neurath,et al.  CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. , 2003, The Journal of clinical investigation.

[60]  A. Hall,et al.  Rho GTPases in cell biology , 2002, Nature.

[61]  A. Hall,et al.  Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. , 2002, Genes & development.

[62]  S. Targan,et al.  6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. , 2002, Gastroenterology.

[63]  I. Vetter,et al.  The Guanine Nucleotide-Binding Switch in Three Dimensions , 2001, Science.

[64]  S. Targan,et al.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.

[65]  G. Fick,et al.  Azathioprine for maintaining remission of Crohn's disease. , 1998, The Cochrane database of systematic reviews.

[66]  R. Modigliani,et al.  Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. , 2000, The Cochrane database of systematic reviews.